SCHEMBL3541850

SCHEMBL3541850

C#Cc1ccc(NC(=O)C=Cc2cccc(Oc3ccnc(C4=NCCN4)c3)c2)cc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KDR P35968 9/20 0.41
BRAF P15056 5/20 0.41
CDK8 P49336 1/20 0.40
SMPD3 Q9NY59 1/20 0.39
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
LMNA P02545 2/20 0.38
HSP90AA1 P07900 1/20 0.38
PKM P14618 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541845 1.00 BLM (0.42) BLMTDP1KDRBRAFCDK8
SCHEMBL3544338 0.93 KDR (0.48) BLMTDP1KDRBRAFCDK8
SCHEMBL3544333 0.93 KDR (0.48) BLMTDP1KDRBRAFCDK8
SCHEMBL3546806 0.91 BLM (0.40) BLMTDP1KDRBRAFCDK8
SCHEMBL3546801 0.91 BLM (0.40) BLMTDP1KDRBRAFCDK8
SCHEMBL3543898 0.89 CDK8 (0.51) BLMTDP1KDRBRAFCDK8
SCHEMBL3553133 0.89 KDR (0.49) BLMTDP1KDRBRAFCDK8
SCHEMBL3539800 0.89 RAF1 (0.45) BLMTDP1KDRCDK8SMPD3
SCHEMBL3543897 0.89 CDK8 (0.51) BLMTDP1KDRBRAFCDK8
SCHEMBL3553130 0.89 KDR (0.49) BLMTDP1KDRBRAFCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652041-B2 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-01-26 US claimed
US-7652041-B2 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-01-26 US disclosed
US-20060160803-A1 Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160803-A1 Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity MAP3K21, HIPK4, MAP3K20 BLM 4800/4885TDP1 2815/4885KDR 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.